uMETHOD Health Publishes Study Showing Favorable Cognitive Outcomes with AI-generated Care Plans

RALEIGH, N.C., Sept. 17, 2026 /CourierPR/ -- uMETHOD Health, a healthtech company based in RTP, North Carolina, has published a peer-reviewed study documenting favorable cognitive outcomes for its AI-generated RestoreU care plans.

According to the Alzheimer's Association, 7.4 million Americans aged 65 and older are living with Alzheimer's or other dementias, and the associated health care, long-term care, and hospice costs are projected to reach $409 billion in 2026. This national burden ultimately lands in the exam room one patient at a time.

RestoreU, a platform developed by uMETHOD Health, delivers repeatable, auditable clinical decision support. It combines comprehensive medical knowledge, patient-specific data, and AI-enabled analysis to enable clinicians to identify, prioritize, and address treatable causes of cognitive impairment within existing clinical workflows. The platform is aligned with Medicare's cognitive assessment and care planning services and has been commercially deployed since 2016.

The study analyzed 345 paired cognitive tests, each comparing a patient with themselves on the same validated instrument at baseline and follow-up, over a mean interval of 14.1 months. The patients in the study averaged 74.6 years of age, 9.0 comorbid conditions, 11.7 medications, and 23 clinically significant drug-drug interactions. These patients presented with a complex array of interacting variables that would be challenging to reconcile by hand during a routine office visit.

The study found that 83.5% of patients improved, remained stable, or declined slowly without transitioning into a worse diagnostic stage. Another 1.7% of patients declined more slowly than typical and transitioned into the next diagnostic state. John Q. Walker, co-founder and Chief Technology Officer of uMETHOD Health and principal inventor of RestoreU, commented, "This is a real-world retrospective study, not a randomized controlled trial. There is no usual-care comparison group, and we're careful not to claim more than the data support. What the data show is that a systematic, AI-supported, multidomain approach to the treatable contributors of cognitive impairment can be delivered consistently and at scale, inside the workflows clinicians already use, and that the resulting cognitive trajectories we observed were favorable."

Behavioral neurologist and Alzheimer’s expert Dr. Marwan Sabbagh added, "Clinicians have spent years debating pharmacotherapeutic approaches while the factors we can actually change for these patients, medications, metabolic health, sleep, nutrition, vascular risk, went unaddressed in routine care. What is remarkable here is not just the outcome. It is that the results reflect real-world outcomes, and that the approach is systematic enough for any physician to repeat."

uMETHOD Health's Assistive AI is designed to improve care for individuals with chronic diseases that have multiple underlying treatable causes. The company has been at the forefront of developing AI-driven solutions to address the complex needs of older adults with cognitive impairments.